2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|January 3, 2020
Johnson & Johnson to Acquire Taris Biomedical
Author(s)Pharmaceutical Technology Editors
Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200.
Advertisement
Johnson & Johnson announced on Dec. 20, 2019 that it will acquire Taris Biomedical, a Lexington, MA-based biotechnology company focused on drug delivery technology for the treatment of bladder diseases. Financial details were not disclosed.
Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200, a silicone-based drug delivery device that continuously releases medication into the bladder, according to a Taris press release.
“The Taris technology provides a first-in-class clinical stage platform to evaluate novel, locally delivered therapeutics for patients with localized bladder cancer,” said Peter Lebowitz, MD, PhD, Global Therapeutic Area head, Oncology, Janssen Research & Development, in the press release. “Together with the Taris team, we look forward to advancing complete regimens to push towards early interception of bladder cancer with the goal of improving outcomes for patients and, ultimately, delivering cures.”
“The Taris technology and scientific team create an unparalleled convergence opportunity with real potential to deliver differentiated, targeted therapeutics for the treatment of patients with localized bladder cancer,” added Mathai Mammen, MD, PhD, global head, Janssen R&D, Johnson & Johnson, in the press release. “We are eager to build upon the proof-of-concept data that the Taris team has generated and advance its clinical development for patients who face a bladder cancer diagnosis, and potentially for other types of cancer in the future.”
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Advertisement
Advertisement